Key facts
- KayoThera’s last known valuation is $20.5M (Jul 2023).
- It has raised $22.7M across 1 recorded rounds; the latest was Early Stage VC ($10.5M) in Mar 2022.
- Notable investors include MassChallenge, WRF Capital, BioAdvance Capital (Conshohocken), 7G Bioventures, Accelerator Life Science Partners — 13 tracked in total.
- KayoThera has filed 2 Form Ds with the SEC, most recently Jul 2023 ($10.5M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for KayoThera
Funding rounds
1 roundsAbout KayoThera
Developer of small-molecule inhibitors designed to treat cardiometabolic diseases and cancer. The company's therapies block a key enzyme in the retinoid and rexinoid nuclear receptor pathways, disrupting tumor cell survival and immune suppression, enabling researchers to improve chemotherapy and immunotherapy outcomes in advanced cases.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2018
- Employees
- 6
- Website
- kayothera.com/
- Ownership
- Privately Held (backing)
KayoThera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KayoThera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KayoThera in its N-PORT filings yet. We sweep new filings monthly.